Wells Fargo lowered the firm’s price target on RxSight (RXST) to $40 from $42 and keeps an Equal Weight rating on the shares. The firm notes RxSight reported preliminary Q4 revenue of $40.2M, largely in line with consensus of $40.4M and its $40.3M estimate. 2025 guidance was ahead of expectations, says Wells.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST: